Experimental Immunotherapy for Eye Cancer Improves Survival in Early Trials

Columbia Ophthalmologist Dr. Brian Marr speaks about an experimental immunotherapy

designed to attack melanoma that has improved one-year survival, according to CUIMC reports.

     The drug trial, led by Columbia Cancer Researcher Richard Carvajal, MD, was conducted

with a small group of patients with advanced uveal melanoma, the most common primary eye

cancer in adults.  Read the full story, here.


                      Caption: Dr. Marr treating a patient at ColumbiaDoctors Third Ave.